Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 270

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 270
---
 Master Services Agreement (1) if the other party is in material breach of the agreement and fails to cure such breach within 30 days of written notice,
subject to certain exceptions; or (2) immediately upon written notice to the other party if the other party (a) becomes insolvent, (b) ceases to function as a going concern, (c) is convicted of or pleads guilty to a charge of
violating any law relating to either party’s business, or (d) engages in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party’s trademark or trade name. In addition, Lifecore
may terminate the agreement if (i) we fail to pay past due invoices upon 30 days’ written notice, or (ii) we reject or fail to respond to a major change or minor change proposed by Lifecore that does not change SEMDEXA’s written
and approved acceptance criteria.

The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for
Lifecore and Semnur.

The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendments
thereto in the forms filed as exhibits to the registration statement of which this prospectus is a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms.

175

Semnur Acquisition

On March 18, 2019, Legacy Scilex acquired Semnur pursuant to the Semnur Acquisition Agreement, Sigma Merger Sub, the Semnur
Equityholders’ Representative, and for limited purposes, Sorrento. Pursuant to the Semnur Acquisition Agreement, Sigma Merger Sub merged with and into Semnur (the “Semnur Acquisition”), with Semnur surviving as Legacy Scilex’s
wholly owned subsidiary.

Pursuant to the Semnur Acquisition Agreement, and upon the terms and subject to the conditions contained
therein, Legacy Scilex also agreed to pay former holders of Semnur’s capital stock (the “Semnur Equityholders”) up to $280.0 million in aggregate contingent cash consideration based on the achievement of certain milestones (which
amount is expected to be charged back to Semnur through an intercompany arrangement), comprised of a $40.0 million payment that will be due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that